MihÃ¡ly JÃ³zsi

List of Publications by Year
in descending order

93 papers	6,131 citations	66343 42 h-index	71685 76 g-index
99 all docs	99 docs citations	99 times ranked	4014 citing authors

#	Article	IF	Citations
1	Complement Factor H-Related Proteins FHR1 and FHR5 Interact With Extracellular Matrix Ligands, Reduce Factor H Regulatory Activity and Enhance Complement Activation. Frontiers in Immunology, 2022, 13, 845953.	4.8	11
2	A Family Affair: Addressing the Challenges of Factor H and the Related Proteins. Frontiers in Immunology, 2021, 12, 660194.	4.8	26
3	Autoantibodies Against the Complement Regulator Factor H in the Serum of Patients With Neuromyelitis Optica Spectrum Disorder. Frontiers in Immunology, 2021, 12, 660382.	4.8	7
4	Mini-Factor H Modulates Complement-Dependent IL-6 and IL-10 Release in an Immune Cell Culture (PBMC) Model: Potential Benefits Against Cytokine Storm. Frontiers in Immunology, 2021, 12, 642860.	4.8	15
5	FHR-5 Serum Levels and CFHR5 Genetic Variations in Patients With Immune Complex-Mediated Membranoproliferative Glomerulonephritis and C3-Glomerulopathy. Frontiers in Immunology, 2021, 12, 720183.	4.8	12
6	Detection of Complement Factor B Autoantibodies by ELISA. Methods in Molecular Biology, 2021, 2227, 141-145.	0.9	3
7	Complement Factor H Family Proteins Modulate Monocyte and Neutrophil Granulocyte Functions. Frontiers in Immunology, 2021, 12, 660852.	4.8	5
8	Pathogenic D76N Variant of Î²2-Microglobulin: Synergy of Diverse Effects in Both the Native and Amyloid States. Biology, 2021, 10, 1197.	2.8	3
9	Editorial: Function and Dysfunction of Complement Factor H. Frontiers in Immunology, 2021, 12, 831044.	4.8	6
10	Interaction of the Factor H Family Proteins FHR-1 and FHR-5 With DNA and Dead Cells: Implications for the Regulation of Complement Activation and Opsonization. Frontiers in Immunology, 2020, 11, 1297.	4.8	21
11	Identification of Neuronal Pentraxins as Synaptic Binding Partners of C1q and the Involvement of NP1 in Synaptic Pruning in Adult Mice. Frontiers in Immunology, 2020, 11, 599771.	4.8	21
12	FHR4â€based immunoconjugates direct complementâ€dependent cytotoxicity and phagocytosis towards HER2â€positive cancer cells. Molecular Oncology, 2019, 13, 2531-2553.	4.6	14
13	C3 glomerulopathy â€" understanding a rare complement-driven renal disease. Nature Reviews Nephrology, 2019, 15, 129-143.	9.6	223
14	Elevated Systemic Pentraxin-3 Is Associated With Complement Consumption in the Acute Phase of Thrombotic Microangiopathies. Frontiers in Immunology, 2019, 10, 240.	4.8	4
15	Functional Characterization of Secreted Aspartyl Proteases in Candida parapsilosis. MSphere, 2019, 4, .	2.9	29
16	Regulation of regulators: Role of the complement factor H-related proteins. Seminars in Immunology, 2019, 45, 101341.	5.6	82
17	Ecotin, a microbial inhibitor of serine proteases, blocks multiple complement dependent and independent microbicidal activities of human serum. PLoS Pathogens, 2019, 15, e1008232.	4.7	24
18	Complement factor H family proteins in their non-canonical role as modulators of cellular functions. Seminars in Cell and Developmental Biology, 2019, 85, 122-131.	5.0	30

#	ARTICLE	IF	CITATIONS
19	Elevated pentraxin-3 is associated with alternative pathway dysregulation in the acute phase of thrombotic microangiopathies. Molecular Immunology, 2018, 102, 222-223.	2.2	1
20	Assessment of the C3b- and iC3b-binding ability of CFHR5 variants. Molecular Immunology, 2018, 102, 141.	2.2	0
21	Self-Damage Caused by Dysregulation of the Complement Alternative Pathway: Relevance of the Factor H Protein Family. Frontiers in Immunology, 2018, 9, 1607.	4.8	39
22	Complement Factor H-Related Protein 4A Is the Dominant Circulating Splice Variant of CFHR4. Frontiers in Immunology, 2018, 9, 729.	4.8	15
23	Infusion Reactions Associated with the Medical Application of Monoclonal Antibodies: The Role of Complement Activation and Possibility of Inhibition by Factor H. Antibodies, 2018, 7, 14.	2.5	6
24	Functional Characterization of Alternative and Classical Pathway C3/C5 Convertase Activity and Inhibition Using Purified Models. Frontiers in Immunology, 2018, 9, 1691.	4.8	50
25	FHR-1 Binds to C-Reactive Protein and Enhances Rather than Inhibits Complement Activation. Journal of Immunology, 2017, 199, 292-303.	0.8	43
26	Interaction of factor H family proteins with DNA and dead cells: Implications for the regulation of opsonization. Molecular Immunology, 2017, 89, 140-141.	2.2	0
27	Relationship between CFHR5 and complement parameters in patients suffering from complement-mediated kidney disorders, with or without CFHR5 mutations. Molecular Immunology, 2017, 89, 177.	2.2	0
28	Analysis of Linear Antibody Epitopes on Factor H and CFHR1 Using Sera of Patients with Autoimmune Atypical Hemolytic Uremic Syndrome. Frontiers in Immunology, 2017, 8, 302.	4.8	18
29	Factor H Family Proteins in Complement Evasion of Microorganisms. Frontiers in Immunology, 2017, 8, 571.	4.8	60
30	The Murine Factor H-Related Protein FHR-B Promotes Complement Activation. Frontiers in Immunology, 2017, 8, 1145.	4.8	13
31	Functional Characterization of the Disease-Associated N-Terminal Complement Factor H Mutation W198R. Frontiers in Immunology, 2017, 8, 1800.	4.8	4
32	Functional characterization of a disease-associated N-terminal factor H mutation. Immunobiology, 2016, 221, 1176.	1.9	0
33	Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients. Immunobiology, 2016, 221, 503-511.	1.9	28
34	Complement factor H modulates the activation of human neutrophil granulocytes and the generation of neutrophil extracellular traps. Molecular Immunology, 2016, 72, 37-48.	2.2	34
35	Heterogeneity but individual constancy of epitopes, isotypes and avidity of factor H autoantibodies in atypical hemolytic uremic syndrome. Molecular Immunology, 2016, 70, 47-55.	2.2	33
36	Factor H inhibits complement activation induced by liposomal and micellar drugs and the therapeutic antibody rituximab in vitro. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 1023-1031.	3.3	22

#	Article	IF	Citations
37	A Case of CFH-Ab Hus Responsive to Plasmapheresis and with Sustained Remission after Initiation of Immunosuppressive Therapy Highlighting the Common Pit Falls of a Complicated Disease. Journal of Clinical & Experimental Nephrology, 2016, 01, .	0.1	0
38	Neutrophil activation during attacks in patients with hereditary angioedema due to C1-inhibitor deficiency. Orphanet Journal of Rare Diseases, 2015, 10, 156.	2.7	24
39	Factor H-related proteins determine complement-activating surfaces. Trends in Immunology, 2015, 36, 374-384.	6.8	130
40	The possible role of factor H in complement activation-related pseudoallergy (CARPA): a failed attempt to correlate blood levels of FH with liposome-induced hypersensitivity reactions in patients with autoimmune disease. European Journal of Nanomedicine, 2015, 7, .	0.6	4
41	Pathogenic Leptospira Species Acquire Factor H and Vitronectin via the Surface Protein LcpA. Infection and Immunity, 2015, 83, 888-897.	2.2	57
42	The Major Autoantibody Epitope on Factor H in Atypical Hemolytic Uremic Syndrome Is Structurally Different from Its Homologous Site in Factor H-related Protein 1, Supporting a Novel Model for Induction of Autoimmunity in This Disease. Journal of Biological Chemistry, 2015, 290, 9500-9510.	3.4	69
43	Factor Hâ€"Related Protein 5 Interacts with Pentraxin 3 and the Extracellular Matrix and Modulates Complement Activation. Journal of Immunology, 2015, 194, 4963-4973.	0.8	75
44	Secreted aspartic protease 2 of Candida albicans inactivates factor H and the macrophage factor H-receptors CR3 (CD11b/CD18) and CR4 (CD11c/CD18). Immunology Letters, 2015, 168, 13-21.	2.5	32
45	Complement Factor H-Antibodyâ€"Associated Hemolytic Uremic Syndrome: Pathogenesis, Clinical Presentation, and Treatment. Seminars in Thrombosis and Hemostasis, 2014, 40, 431-443.	2.7	41
46	Autoantibodies to complement components in C3 glomerulopathy and atypical hemolytic uremic syndrome. Immunology Letters, 2014, 160, 163-171.	2.5	50
47	Factor H-Related Proteins. Methods in Molecular Biology, 2014, 1100, 225-236.	0.9	17
48	An Engineered Construct Combining Complement Regulatory and Surface-Recognition Domains Represents a Minimal-Size Functional Factor H. Journal of Immunology, 2013, 191, 912-921.	0.8	70
49	Anti-factor H antibody affecting factor H cofactor activity in a patient with dense deposit disease. CKJ: Clinical Kidney Journal, 2012, 5, 133-136.	2.9	20
50	Factor H: A Complement Regulator in Health and Disease, and a Mediator of Cellular Interactions. Biomolecules, 2012, 2, 46-75.	4.0	115
51	Leptospiral Immunoglobulin-like Proteins Interact With Human Complement Regulators Factor H, FHL-1, FHR-1, and C4BP. Journal of Infectious Diseases, 2012, 205, 995-1004.	4.0	132
52	Atypical Hemolytic Uremic Syndrome-Associated Variants and Autoantibodies Impair Binding of Factor H and Factor H-Related Protein 1 to Pentraxin 3. Journal of Immunology, 2012, 189, 1858-1867.	0.8	62
53	Factor H-related Protein 4 Activates Complement by Serving as a Platform for the Assembly of Alternative Pathway C3 Convertase via Its Interaction with C3b Protein. Journal of Biological Chemistry, 2012, 287, 19528-19536.	3.4	77
54	Differential Interaction of the Two Related Fungal SpeciesCandida albicansandCandida dubliniensiswith Human Neutrophils. Journal of Immunology, 2012, 189, 2502-2511.	0.8	31

#	Article	IF	Citations
55	Screening for anti-factor B autoantibody in a patient with acute renal injury due to dense deposit disease. Clinical Nephrology, 2012, 77, 85-86.	0.7	0
56	Factor H-related protein 1 neutralizes anti-factor H autoantibodies in autoimmune hemolytic uremic syndrome. Kidney International, 2011, 80, 397-404.	5.2	70
57	Anti-Complement Autoantibodies in Membranoproliferative Glomerulonephritis and Dense Deposit Disease. , 2011, , .		1
58	Role of pH-regulated antigen 1 of Candida albicans in the fungal recognition and antifungal response of human neutrophils. Molecular Immunology, 2011, 48, 2135-2143.	2.2	25
59	Human Pentraxin 3 Binds to the Complement Regulator C4b-Binding Protein. PLoS ONE, 2011, 6, e23991.	2.5	68
60	Interaction of the long pentraxin PTX3 with soluble complement inhibitors. Molecular Immunology, 2010, 47, 2234-2235.	2.2	1
61	Factor H and Factor H-Related Protein 1 Bind to Human Neutrophils via Complement Receptor 3, Mediate Attachment to Candida albicans, and Enhance Neutrophil Antimicrobial Activity. Journal of Immunology, 2010, 184, 912-921.	0.8	107
62	Molecular basis of C-reactive protein binding and modulation of complement activation by factor H-related protein 4. Molecular Immunology, 2010, 47, 1347-1355.	2.2	38
63	Anti-factor B autoantibody in dense deposit disease. Molecular Immunology, 2010, 47, 1476-1483.	2.2	97
64	Functional analyses indicate a pathogenic role of factor H autoantibodies in atypical haemolytic uraemic syndrome. Nephrology Dialysis Transplantation, 2010, 25, 136-144.	0.7	78
65	Monomeric CRP contributes to complement control in fluid phase and on cellular surfaces and increases phagocytosis by recruiting factor H. Cell Death and Differentiation, 2009, 16, 1630-1640.	11.2	129
66	Human complement factor H-related protein 4 binds and recruits native pentameric C-reactive protein to necrotic cells. Molecular Immunology, 2009, 46, 335-344.	2.2	56
67	Autoimmune forms of thrombotic micorangiopathy and membranoproliferative glomerulonephritis: Indications for a disease spectrum and common pathogenic principles. Molecular Immunology, 2009, 46, 2801-2807.	2.2	44
68	Autoantibodies in haemolytic uraemic syndrome (HUS). Thrombosis and Haemostasis, 2009, 101, 227-232.	3.4	76
69	Autoantibodies in haemolytic uraemic syndrome (HUS). Thrombosis and Haemostasis, 2009, 101, 227-32.	3.4	33
70	Factor H family proteins and human diseases. Trends in Immunology, 2008, 29, 380-387.	6.8	230
71	Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood, 2008, 111, 1512-1514.	1.4	332
72	Deletion of Complement Factor Hâ€“Related Genes CFHR1 and CFHR3 Is Associated with Atypical Hemolytic Uremic Syndrome. PLoS Genetics, 2007, 3, e41.	3.5	285

#	Article	IF	Citations
73	Hemolytic Uremic Syndrome: A Factor H Mutation (E1172Stop) Causes Defective Complement Control at the Surface of Endothelial Cells. Journal of the American Society of Nephrology: JASN, 2007, 18, 506-514.	6.1	59
74	Antiâ€“factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome. Blood, 2007, 110, 1516-1518.	1.4	222
75	The C-terminus of complement factor H is essential for host cell protection. Molecular Immunology, 2007, 44, 2697-2706.	2.2	95
76	Role of complement and Factor H in hemolytic uremic syndrome. , 2006, , 85-109.		4
77	Complement and diseases: Defective alternative pathway control results in kidney and eye diseases. Molecular Immunology, 2006, 43, 97-106.	2.2	205
78	The C-terminus of complement regulator Factor H mediates target recognition: evidence for a compact conformation of the native protein. Clinical and Experimental Immunology, 2006, 144, 342-352.	2.6	147
79	Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II). Kidney International, 2006, 70, 42-50.	5.2	180
80	Two factor H-related proteins from the mouse: expression analysis and functional characterization. Immunogenetics, 2006, 58, 883-893.	2.4	24
81	Factor H and Atypical Hemolytic Uremic Syndrome: Mutations in the C-Terminus Cause Structural Changes and Defective Recognition Functions. Journal of the American Society of Nephrology: JASN, 2006, 17, 170-177.	6.1	115
82	FHR-4A: a new factor H-related protein is encoded by the human FHR-4 gene. European Journal of Human Genetics, 2005, 13, 321-329.	2.8	45
83	Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease). Journal of Medical Genetics, 2005, 43, 582-589.	3.2	197
84	Binding of Complement Factor H to Endothelial Cells Is Mediated by the Carboxy-Terminal Glycosaminoglycan Binding Site. American Journal of Pathology, 2005, 167, 1173-1181.	3.8	108
85	Regulation of B-cell activation by complement receptors CR1 (CD35) and CR2 (CD21)â€"possible involvement in the pathogenesis of autoimmune diseases. Autoimmunity Reviews, 2004, 3, 624-625.	5.8	0
86	Attachment of the soluble complement regulator factor H to cell and tissue surfaces: relevance for pathology. Histology and Histopathology, 2004, 19, 251-8.	0.7	66
87	Genetic screening in haemolytic uraemic syndrome. Current Opinion in Nephrology and Hypertension, 2003, 12, 653-657.	2.0	10
88	Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. Journal of Clinical Investigation, 2003, 111, 1181-1190.	8.2	315
89	Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. Journal of Clinical Investigation, 2003, 111, 1181-1190.	8.2	71
90	Complement Receptor Type 1 (CD35) Mediates Inhibitory Signals in Human B Lymphocytes. Journal of Immunology, 2002, 168, 2782-2788.	0.8	85

#	Article	IF	Citations
91	Characterization of factor H-related cell membrane molecules expressed by human B lymphocytes and neutrophil granulocytes. Immunology Letters, 2001, 77, 55-62.	2.5	2
92	Mannan-binding lectin and C1q bind to distinct structures and exert differential effects on macrophages. European Journal of Immunology, 2000, 30, 1706-1713.	2.9	27
93	A further link between innate and adaptive immunity: C3 deposition on antigen-presenting cells enhances the proliferation of antigen-specific T cells.. International Immunology, 1998, 10, 1923-1930.	4.0	69